Clinical significance of therapy using branched‐chain amino acid granules in patients with liver cirrhosis and hepatocellular carcinoma
- 15 August 2013
- journal article
- Published by Wiley in Hepatology Research
- Vol. 44 (2) , 149-158
Abstract
The liver is the major organ for the metabolism of protein, fat and carbohydrate. A nutritional approach is required in the treatment of cirrhosis, which is frequently complicated with protein–energy malnutrition. Several advanced treatment approaches for hepatocellular carcinoma (HCC) have been established in the past decade. HCC is often complicated by cirrhosis, so treatment of the underlying liver diseases is also necessary to improve the prognosis. Branched‐chain amino acid (BCAA) granules were developed originally for the treatment of hypoalbuminemia associated with decompensated cirrhosis. However, subsequent studies found various other pharmacological actions of this agent. We review the clinical significance of therapy using BCAA granules in patients receiving different treatment approaches for cirrhosis and HCC based on the published work as well as our own data.Keywords
This publication has 95 references indexed in Scilit:
- Effects of branched‐chain amino acid granules on serum albumin level and prognosis are dependent on treatment adherence in patients with liver cirrhosisHepatology Research, 2012
- Epidemiology of Viral Hepatitis and Hepatocellular CarcinomaGastroenterology, 2012
- Radiofrequency Ablation for Hepatocellular Carcinoma: 10-Year Outcome and Prognostic FactorsAmerican Journal of Gastroenterology, 2012
- Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma in JapanCancers, 2012
- Nutraceutical Approach for Preventing Obesity-Related Colorectal and Liver CarcinogenesisInternational Journal of Molecular Sciences, 2012
- Branched-chain amino acid treatment before transcatheter arterial chemoembolization for hepatocellular carcinomaWorld Journal of Gastroenterology, 2012
- Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference reportThe Lancet Oncology, 2012
- Long-term interferon therapy after radiofrequency ablation is effective in treating patients with HCV-associated hepatocellular carcinomaHepatology International, 2010
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Phase II Study of Sorafenib in Patients With Advanced Hepatocellular CarcinomaJournal of Clinical Oncology, 2006